Related Experiment Videos
Alpha 1-antitrypsin deficiency, complement activation, and chronic liver disease
E T Littleton1, L Bevis, L J Hansen
1Department of Immunology, King's College School of Medicine and Dentistry, London.
Journal of Clinical Pathology
|October 1, 1991
Summary
Children with alpha 1-antitrypsin (AT) deficiency show increased complement system activation, particularly in severe liver disease. This suggests the complement system plays a role in the liver damage associated with alpha 1-AT deficiency.
Area of Science:
- Immunology
- Hepatology
- Genetics
Background:
- The complement system is a key mediator of inflammation, regulated by inhibitors like alpha 1-antitrypsin (AT).
- Alpha 1-AT deficiency is a genetic disorder linked to chronic liver disease in children.
- Understanding complement system's role in alpha 1-AT deficiency-related liver disease is crucial.
Purpose of the Study:
- To investigate complement system activation in children with alpha 1-AT deficiency and varying degrees of liver disease.
- To determine if complement activation correlates with the severity of liver disease in alpha 1-AT deficiency.
Main Methods:
- Studied 34 children with alpha 1-AT deficiency (minimal, moderate, severe liver disease) and 38 healthy controls.
- Measured complement components C3, C4, and the C3d fragment.
- Calculated the C3d:C3 ratio as a marker of complement activation.
Main Results:
- Children with severe liver disease had lower C3 and C4 levels, suggesting impaired protein synthesis or complement consumption.
- The C3d fragment was elevated in all alpha 1-AT deficiency patient groups compared to controls.
- The C3d:C3 ratio increased with disease severity, indicating heightened complement activation.
Conclusions:
- Complement activation is elevated in children with alpha 1-AT deficiency.
- The degree of complement activation correlates with the severity of liver disease.
- The complement system may contribute to the pathogenesis of chronic liver disease in alpha 1-AT deficiency.